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Abstract
Inteins catalyze protein splicing in a fashion similar to how self-splicing introns catalyze RNA splicing. Split-
inteins catalyze precise ligation of two separate polypeptides through trans-splicing in a highly specific man-
ner. Here we report a method of using protein trans-splicing to circumvent the packaging size limit of gene
therapy vectors. To demonstrate this method, we chose a large dystrophin gene and an adeno-associated viral
(AAV) vector, which has a small packaging size. A highly functional 6.3-kb Becker-form dystrophin cDNA was
broken into two pieces and modified by adding appropriate split-intein coding sequences, resulting in split-
genes sufficiently small for packaging in AAV vectors. The two split-genes, after codelivery into target cells,
produced two polypeptides that spontaneously trans-spliced to form the expected Becker-form dystrophin pro-
tein in cell culture in vitro. Delivering the split-genes by AAV1 vectors into the muscle of a mouse model of
Duchenne muscular dystrophy rendered therapeutic gene expression and benefits.
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Introduction
THE PROTEIN trans-SPLICING METHOD was inspired by thediscovery of a natural case of protein trans-splicing in
the photosynthetic cyanobacterium Synechocystis sp. PCC
6803 (Wu et al., 1998a). The DnaE protein of this organism is
encoded in two split-genes, with one gene encoding the N-
terminal part of DnaE followed by a 123-amino acid split-in-
tein sequence and another gene encoding the C-terminal part
of DnaE preceded by a 36-amino acid split-intein sequence.
Two polypeptides expressed from the split-genes undergo
spontaneous protein trans-splicing to produce the complete
DnaE protein. The splicing reaction is catalyzed by the split-
intein sequences, removes precisely the split-intein se-
quences, and joins specifically the N- and C-terminal parts
of DnaE with a peptide bond. Artificial split-inteins have also
been engineered from contiguous inteins that are naturally
embedded in host proteins and catalyze cis-splicing reac-
tions. For example, the split-intein used in this study was en-
gineered from a contiguous DnaB intein by using only its N-
terminal 106-amino acid sequence (N-intein) and C-terminal
48-amino acid sequence (C-intein) (Wu et al., 1998b). Split-
intein and contiguous inteins have been found in many mi-
croorganisms but not in humans. Because protein splicing is
catalyzed by the intein itself, in general without host speci-
ficity and assistance from other cellular factors, it was
thought that a microbial intein could work in human cells in
a human protein, provided that the intein was placed im-
mediately before a nucleophilic residue (serine, cysteine, or
threonine) in the human protein.
Dystrophin gene therapy for Duchenne muscular dystro-
phy (DMD) presented an ideal test case for the protein trans-
splicing method. DMD is caused by recessive mutations in
the dystrophin gene and is the most common and lethal
childhood muscle disorder, affecting 1 in every 3500 male
births (Koenig et al., 1987). Gene therapy offers a promising
treatment for DMD, and the adeno-associated viral (AAV)
vector is the most efficient and nontoxic vehicle for deliver-
ing genes to muscle tissues, as has been demonstrated with
a number of muscle genes and reporter genes (Xiao et al.,
1996, 2000; Fisher et al., 1997; Snyder et al., 1997; Hartigan-
O’Connor and Chamberlain, 2000; Wang et al., 2000; Watchko
et al., 2002). Because AAV can optimally package approxi-
mately 4.7 kb of DNA, an AAV vector has less than 4 kb of
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room to accommodate a transgene in addition to the required
accessory cis-acting sequences such as the promoter,
polyadenylation signal, flanking inverted terminal repeats
(ITRs), and so on. The room available for the transgene be-
comes even smaller when large regulatory elements or tis-
sue-specific enhancers are used. Although the full-length dy-
strophin gene has a coding sequence of 11 kb, a 6.3-kb
Becker-form dystrophin cDNA has proven highly functional
(England et al., 1990; Phelps et al., 1995). This cDNA was iso-
lated from a Becker muscular dystrophy patient more than
60 years of age with mild symptoms (England et al., 1990).
However, this 6.3-kb dystrophin cDNA is still too large for
the AAV vector. We hypothesized that this problem could
be resolved by a protein trans-splicing strategy. In this re-
port, we have split the 6.3-kb dystrophin cDNA into two
pieces and linked the intein catalytic elements at the junc-
tions of the split site. These two separate coding sequences
were packaged in AAV1 vectors under the control of a cy-
tomegalovirus (CMV) promoter. Simultaneous delivery of
the dual vectors resulted in efficient production and splic-
ing of the two polypeptides to form one full-sized Becker-
form dystrophin both in vitro and in vivo in mdx mice.
Materials and Methods
Construction of split dystrophin genes
DNA fragments from the dystrophin gene and the split-
inteins were amplified by polymerase chain reaction (PCR),
using high-fidelity Pyrococcus furiosus (Pfu) DNA poly-
merase, and inserted into the rAAV plasmid pXXUF1 (Li et
al., 1999) between the NotI and SalI cutting sites. The N-dys
gene contains the first 1066 codons and a 10-bp 5 untrans-
lated leader sequence of the dystrophin gene. The C-dys gene
contains the last 917 codons and an 8-bp 5 untranslated
leader sequence of the dystrophin gene. Split-intein coding
sequences were from the Synechocystis sp. PCC 6803 (Ssp)
DnaB intein or the Rhodothermus marinus (Rma) DnaB intein,
with the first 106 codons placed in the N-dys gene and the
last 51 codons in the C-dys gene (Liu and Hu, 1997). DNA
sequences were confirmed by sequencing all of the intein-
containing dystrophin split-genes.
Transfection and Western blot analysis
A total of 25 g of plasmid DNA was dissolved in 1 ml of
0.25 M CaCl2 and quickly mixed with 1 ml of HBS buffer (50
mM HEPES, 280 mM NaCl, and 1.5 mM Na2HPO4, pH 7.12)
before adding it to human 293 cells for transfection. Eight to
12 hr after transfection, the medium was replaced with fresh
Dulbecco’s modified Eagle’s medium (GIBCO DMEM; In-
vitrogen, Carlsbad, CA) containing 10% fetal bovine serum
(FBS) and antibiotics. The cells were harvested 48 hr post-
transfection and lysed in sodium dodecyl sulfate (SDS)- and
dithiothreitol (DTT)-containing gel-loading buffer in a boil-
ing water bath. Total cellular proteins were resolved on an
SDS–8% polyacrylamide gel and blotted onto nitrocellulose
membrane. Western blot analysis was done with either
monoclonal antibody NCL-DYS2 (Novocastra brand, dis-
tributed by Vector Laboratories, Burlingame, CA) against the
C-terminal part of dystrophin or the monoclonal antibody
NCL-DYS3 (Novocastra) against the N-terminal part of 
dystrophin.
Experiments with mdx mice
Production and CsCl density gradient purification of
AAV1 vectors were carried out according to previously pub-
lished methods (Snyder et al., 1996). Muscle cryosections
(thickness, 8 m) were immunofluorescently stained with a
Mouse on Mouse (M.O.M.) kit (Vector Laboratories) to block
the endogenous immunoglobulin background on the sec-
tions, according to the manufacturer’s protocol. The cryosec-
tions were immediately treated with the blocking buffer
without the fixation step. The immunofluorescence staining
was done with either the NCL-DYS2 or NCL-DYS3 antibody
(described previously), followed by a secondary rabbit anti-
mouse antibody labeled with either the green fluorescent dye
fluorescein isothiocyanate (FITC) or the red fluorescent dye
cyanine 3 (Cy3; Novocastra), respectively. Alternatively, rab-
bit polyclonal antibodies against human dystrophin rod do-
main repeats R1R2 or R22R23 were used for the immuno-
fluorescence staining of mouse muscle.
Results and Discussion
As illustrated in Fig. 1, a large gene can be split into two
pieces, and each piece is linked with an appropriate coding
sequence of a split-intein. Each of the resulting split-genes,
FIG. 1. An illustration of the protein trans-splicing method
for overcoming the size limitation of gene delivery vectors.
A large gene is converted into two smaller, intein-contain-
ing split-genes and delivered into a target cell by means of
two vectors. Expression of the two split-genes produces two
intein-containing split-proteins that spontaneously undergo
protein trans-splicing to produce the mature protein.
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containing the intein coding sequence, is sufficiently small
to be packaged into an AAV vector. The two split-genes are
both delivered into a target cell to produce the correspond-
ing intein-containing split-proteins that spontaneously un-
dergo protein trans-splicing to produce the mature protein,
in this case the Becker-form dystrophin. Simultaneous de-
livery of the two split-genes into the same target cells, espe-
cially in muscle cells, is readily achievable, because a target
cell typically receives several viral particles via a standard
AAV-based gene delivery method.
To accomplish the above-described goal, we first wished
to identify an optimal split site in the dystrophin gene, so
that the resulting dystrophin fragments would be suitable
for efficient protein trans-splicing. Dystrophin is a large, rod-
like protein having an N-terminal globular domain, a C-ter-
minal globular domain, and a long central rod domain con-
sisting of 24 coiled-coil repeats (rods) (Koenig and Kunkel,
1990). The central rod domain of the Becker-form dystrophin
consists of approximately 8.5 rods, and each rod is thought
to fold independently. On the basis of this structure, we se-
lected four alternative split sites near the middle of the 6.3-
kb dystrophin gene. In the corresponding 1983-amino acid
Becker dystrophin protein sequence, the four split sites are
in front of amino acid residues S950, T985, S1067, and S1101,
respectively, so that an intein will be placed in front of a nu-
cleophilic amino acid (cysteine, threonine, or serine) that is
required for protein splicing. We initially tested these split
sites for protein trans-splicing in Escherichia coli cells. A 420-
amino acid middle portion of the dystrophin protein (amino
acid residues 855–1274 containing the four split sites) was
used in this test, because the complete dystrophin protein
was difficult to produce in E. coli. We also chose a previously
engineered Ssp DnaB split-intein that showed efficient trans-
splicing in a model protein in E. coli (Wu et al., 1998b).
Adding the coding sequences of this split-intein to each of
the four split sites produced a pair of intein-containing 
dystrophin split-genes. Each pair of the split-genes (as a two-
gene operon on a plasmid) was expressed in E. coli cells to
produce a corresponding pair of intein-containing dys-
trophin polypeptides and to detect protein trans-splicing.
Only one of the four different pairs of split-genes, which cor-
responded to the split site at S1067, showed a detectable level
of protein trans-splicing, and the splicing efficiency was es-
timated to be 50% (data not shown).
The preceding test results allowed us to select the S1067
split site as the optimal site for subsequent studies. The S1067
split site is located inside coiled-coil repeat number 6 (rod 6)
of the Becker-form dystrophin, which corresponds to rod 22
FIG. 2. Application of the protein
trans-splicing method to dystrophin
and AAV vectors. (A) Schematic il-
lustration of the experimental proce-
dure. The 6.3-kb Becker dystrophin
cDNA is split at the site marked with
an arrowhead, and the split-intein
coding sequences (N and C) are
added as illustrated. The recombi-
nant split-genes (N-dys gene and C-
dys gene) are each packaged in an
AAV vector, which contains inverted
terminal repeats (ITRs), a poly(A)
site, and the CMV promoter. After in-
fection of a target cell with both split-
genes and after gene expression, the
resulting split-proteins (N-dys pro-
tein and C-dys protein) sponta-
neously undergo protein trans-splic-
ing to produce the Becker dystrophin
protein. (B) Amino acid sequences of
the N-dys protein and the C-dys pro-
tein, which were generated with the
S1067 split site of Becker dystrophin
and the Ssp DnaB split-intein. Only
sequences near the dystrophin–in-
tein junctions are shown; the lengths
of omitted sequences are indicated
with numbers in parentheses, and
the intein sequences are indicated
with boldface letters. Sequences of
helix 2 and helix 3 inside the sixth of
the 8.5 spectrin-like coiled-coil re-
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of the full-length dystrophin (Koenig et al., 1987; Koenig and
Kunkel, 1990). More specifically, the split site is inside an un-
structured turn between helix 2 and helix 3 of the spectrin-
like triple-helical coiled-coil structure of rod 6 (Fig. 2B). The
known close packing between helix 2 and helix 3 may have
helped bringing together the two polypeptides for the trans-
splicing, although the split-intein parts (intein-N and intein-
C) can associate tightly without help from the flanking ex-
teins (Wu et al., 1998b). Because the split site is located in the
central rod domain of dystrophin, the resulting dystrophin
polypeptides are thought to fold independently before splic-
ing.
After finding the optimal S1067 split site, we constructed
a pair of intein-containing split-genes, using the complete
Becker dystrophin gene (Fig. 2). These split-genes are named
the N-dys gene and C-dys gene, respectively. The N-dys
gene encodes the N-dys protein consisting of the N-terminal
half (residues 1–1066) of Becker dystrophin followed by the
N part (106 amino acids) of the Ssp DnaB split-intein,
whereas the C-dys gene encodes the C-dys protein consist-
ing of the C part (51 amino acids) of the Ssp DnaB split-in-
tein followed by the C-terminal half (residues 1067–1983) of
Becker dystrophin. The two split-genes were inserted in two
separate AAV vector plasmids under the control of a strong
CMV promoter for expression in mammalian cells.
To test for dystrophin synthesis through protein trans-
splicing, the two AAV vector plasmids containing the intein-
containing dystrophin split-genes were introduced into tis-
sue-cultured human cells (the 293 cell line) through DNA
cotransfection, and the resulting protein products were an-
alyzed on Western blots (Fig. 3A). In cells transfected with
both the N-dys gene and the C-dys gene, protein trans-splic-
ing generated the mature dystrophin protein. As a negative
control, cells transfected with either the N-dys gene or the
C-dys gene alone produced only the corresponding precur-
sor protein, as expected. The mature dystrophin protein was
first identified on the basis of the fact that its apparent size
closely matched its predicted size, which was determined by
polyacrylamide gel electrophoresis under denaturing and re-
ducing conditions. It was further identified by the fact that
it was recognized both with an antibody against the N-ter-
minal part of dystrophin and with an antibody against the
C-terminal part of dystrophin. Small amounts of the N-dys
and C-dys proteins remained unspliced, indicating that the
protein trans-splicing did not go to completion. The remain-
ing N- and C-dys proteins were heterogeneous in size, sug-
gesting partial degradation of these proteins.
To improve the efficiency of protein trans-splicing in 
dystrophin synthesis, we replaced the Ssp DnaB split-intein
with an Rma DnaB split-intein in the preceding experiment.
The Rma DnaB intein shares 74% sequence similarity with
the Ssp DnaB intein but is from a thermophilic organism (Liu
and Hu, 1997). Higher efficiency protein trans-splicing was
observed with the Rma DnaB split-intein, with nearly all of
the N-dys protein and C-dys protein converted into mature
dystrophin protein (Fig. 3A). To achieve this efficient trans-
splicing, a 3:1 ratio of the N-dys gene relative to the C-dys
gene was used in the cotransfection experiment, as using
equal amounts of the N-dys gene and the C-dys gene re-
sulted in less mature dystrophin and excess amounts of un-
spliced C-dys protein (data not shown). This may be ex-
plained by a more rapid degradation of the N-dys protein,
as seen in the mdx mouse, where a premature stop codon in
the dystrophin gene does not lead to an accumulation of the
expected N-terminal partial dystrophin.
To test the protein trans-splicing method in an animal
model, the two intein-containing dystrophin split-genes
(N-dys gene and C-dys gene) were packaged into AAV1
vectors and coinjected into the leg muscle (gastrocnemius)
of mdx mice, a commonly used animal model of Duchenne
muscular dystrophy. The production of functional dys-
trophin through protein trans-splicing was revealed by im-
munofluorescence staining of muscle thin cryosections,
separately with an anti-N-dys antibody recognizing the N-
terminal part of dystrophin and with an anti-C-dys anti-
body recognizing the C-terminal part of dystrophin. As
shown in Fig. 3B, the anti-N-dys and anti-C-dys antibod-
ies revealed overlapping and submembrane staining pat-
terns in the muscle cross-sections. The submembrane lo-
calization and recognition by the anti-N-dys antibody are
strong indicators of a mature dystrophin, because it is
known that the N-terminal part of dystrophin alone is un-
able to localize to the submembrane region and is rapidly
degraded in mdx mice. The submembrane localization of
dystrophin, as revealed with the anti-N-dys antibody, was
observed in nearly 100% of the myofibers of treated mdx
muscle at the site of the local injection, indicating dys-
trophin production through trans-splicing in these cells.
The trans-spliced dystrophin protein rendered therapeutic
benefits to the dystrophic muscle by improving muscle
morphology and histology. For example, the dystrophin-
positive myofibers showed more uniform sizes and few
centrally localized nuclei (Fig. 3B, panels b and c), whereas
the untreated mdx muscle showed the extensive presence
of centrally localized nuclei, a sign of muscle degeneration
and regeneration (Fig. 3B, panel a). All these indicate that
mature and functional dystrophin was produced in the
muscle cells of mdx mice through efficient protein trans-
splicing, which opens up a new avenue of dystrophin gene
therapy for Duchenne muscular dystrophy.
Our findings demonstrated that the protein trans-splicing
method could be used to overcome the size limitation of gene
therapy vectors, particularly the AAV vectors. In the current
study, this method nearly doubled the size range of genes
that can be delivered by AAV vectors. This method can po-
tentially expand the size range even further, if one splits a
gene into three or more parts and trans-splice the resulting
protein parts, using two or more non-cross-reacting split-in-
teins. The protein trans-splicing method should be generally
applicable to other large therapeutic genes besides the dys-
trophin gene, with notable examples including the cystic fi-
brosis transmembrane conductance regulator (CFTR) gene
for cystic fibrosis, the factor VIII gene for hemophilia A (Chao
et al., 2002; Mah et al., 2003; Chen et al., 2007), and other large
muscle genes such as the laminin-2 and dysferlin genes im-
plicated in congenital muscular dystrophy and limb girdle
muscular dystrophy 2B. The protein trans-splicing method
should also be generally applicable to other viral vectors. For
example, the 11-kb complete dystrophin gene, in the form of
two intein-containing pieces, may then be packaged in two
classic retroviral or lentiviral vectors to produce a full-length
dystrophin protein.
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FIG. 3. Observation of dystrophin produc-
tion and function, using the protein trans-
splicing method. (A) Western blot analysis of
dystrophin production. The human 293 cell
line was transfected with either the N-dys
gene or C-dys gene, or both, as indicated (–,
absent; , present), using a total of 25 g of
plasmid DNA per transfection. Cells were
harvested 48 hr after transfection, and 50
g of total cellular protein was resolved by
polyacrylamide gel electrophoresis under de-
naturing (SDS) and reducing (DTT) condi-
tions. Western blotting was done to visualize
dystrophin, using the monoclonal antibody
NCL-DYS3 against the N-terminal part of dy-
strophin (Anti-N-dys) or the monoclonal an-
tibody NCL-DYS2 against the C-terminal
part of dystrophin (Anti-C-dys). The N-dys
protein (marked with the letter N), the C-dys
protein (marked with the letter C), and ma-
ture dystrophin (marked with the letters N-
C) have predicted sizes of 135, 111, and 212
kDa, respectively. In lanes 2, 3, and 5, the N-
dys and C-dys proteins contain the Ssp DnaB
split-intein. In lanes 4 and 6, the N-dys and
C-dys proteins contain the Rma DnaB split-
intein. (B) Immunofluorescence staining of
functional dystrophin. The gastrocnemius
muscles of 3-week-old male mdx mice were
coinjected with AAV1-N-dys and AAV1-C-
dys vectors and examined after 6 months.
Each muscle was injected with 40 l of
AAV1-N-dys (1.5  1011 vector genomes [VG]) and AAV1-C-dys (0.5  1011 VG) at a 3:1 ratio. Cryosections of mdx muscle
were stained immunofluorescently either with a rabbit anti-R1R2 antibody against the N-terminal part of dystrophin (panel
b) or a rabbit anti-R22R23 antibody against the C-terminal part of dystrophin (panel c). As a negative control, a cryosec-
tion of untreated mdx muscle was stained immunofluorescently with the anti-R1R2 antibody (panel a). All panels were then
counterstained for cell nuclei with DAPI (blue). Note the lack of centrally localized nuclei in the AAV-treated muscle, in-
dicating the protective effect of the gene vectors.
The protein trans-splicing method shows certain unique
advantages as well as disadvantages, when compared with
other, similar methods such as the dual AAV vectors (Duan
et al., 2000; Nakai et al., 2000; Sun et al., 2000; Yan et al.,
2000). A major advantage is its precise and orientation-spe-
cific ligation of the two split gene products. Splitting a large
gene into two pieces and packaging them in separate vec-
tors is a well-studied strategy by which to overcome the
size limitation of AAV vectors. The dual AAV vector meth-
ods relied on heterodimerization of two separate AAV vec-
tor DNA molecules and, thus, the fusion of the two split
half-genes inside a target cell. Because the fusion of vectors
A and B appears random in orientation whereas single AAV
vector DNA tends to self-circularize, the theoretical proba-
bility of the correct tail-to-head fusion of vector A DNA and
vector B DNA is significantly less than 25% of the intro-
duced dual vectors. Another dual vector method relied on
homologous DNA recombination to fuse the split-genes in
a target cell (Duan et al., 2001), but homologous recombi-
nation in mammalian cells is notoriously inefficient. In con-
trast, the protein trans-splicing method does not require
vector DNA dimerization or homologous recombination.
Each split-gene vector functions on its own to produce the
precursor split-proteins. The protein molecules A and B are
spontaneously ligated effectively and specifically in a pre-
cise tail-to-head orientation by the intein sequences. Other
methods of handling the packaging limits of AAV include
the use of extremely small promoters (Flotte et al., 1993;
Sarkar et al., 2003). But small promoters often result in lower
gene expression and tissue specificity. Miniaturized genes
have also been constructed by deleting putatively
nonessential regions of large genes (Zhang et al., 1998;
Wang et al., 2000; Harper et al., 2002; Qiao et al., 2005), but
many genes may not tolerate large deletions without los-
ing at least some known or unknown functions.
A potential drawback of the protein trans-splicing method
is the use of intein sequences that may be immunogenic, al-
though this problem was not observed in our studies of mdx
mice. Should this problem occur, immunosuppression could
be used to curb it. Alternatively, tissues with immune priv-
ilege such as the CNS and eye could be used as the preferred
targets. In addition, one might be able to select the least im-
munogenic intein sequences from the large number of avail-
able and different split-inteins. Finally, the efficiency of trans-
splicing may still improve. We have observed different
splicing efficiencies with different split-inteins (Ssp DnaB
split-intein vs. Rma DnaB split-intein) and with different split
sites in the dystrophin protein. A future improvement of the
A
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protein trans-splicing method will be to achieve near 100%
splicing efficiency through better choices of the split-intein
and optimization of the split site in the host proteins. In sum-
mary, the protein trans-splicing method provides a novel al-
ternative approach to overcome the packaging limit of gene
vectors.
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